 |
|
|
| |
Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Z. Younossi1, B. Bacon2, M. Curry3, D. Dieterich4, S.L. Flamm5, K.Kowdley6, S.Milligan7, C. Nwankwo8, N. Tsai9, and N. Afdhal3
1Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA USA, 2Saint Louis University School of Medicine, St. Louis, MO USA, 3Beth Israel Deaconess Medical Center, Boston, MA USA, 4Icahn School of Medicine at Mount Sinai, New York, NY USA, 5Northwestern University Feinberg School of Medicine, Chicago IL USA, 6Liver Care Network, Swedish Medical Center, Seattle, WA USA, 7Trio Health Analytics, La Jolla, CA USA, 8Merck & Co., Inc., Kenilworth, NJ USA and 9Queens Medical Center, University of Hawaii, Honolulu, HI USA
|
| |
|
|
|
|
|
